Topics

Articles

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

Forecasting the Effect of Out-of-Pocket Cost Changes for HIV Medication

In order to provide both profitability and medication access, a balancing act is required.

A Pharma Pricing and Agreements Primer in Today's Complex Landscape

Duplicate rebates have resulted in revenue leakage for manufacturers.

The Impact of 340B on Commercial Contracts

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures. 

A Behind-the-Scenes Look at Drug Price Markups 

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law PLLC, discusses recent moves by CVS and Express Scripts to follow Mark Cuban's drug plus model.

Ron Lanton, Partner, Lanton Law PLLC, Discusses New Drug Plus Pricing Models

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

How Financialization Has Impacted the US Healthcare System

All healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives. 

In the Shadows of the Drug Affordability Debate, Patients Pay the Ultimate Price 

Analysis examines how social and healthcare factors play a role. 

Study Provides Look Into Surgeons' Opioid Prescribing Patterns

Soaring healthcare costs show little sign of abating in 2024, and concerns about the affordability of medications and medical services continue to grow, despite investments in technology, clinical innovation, and efforts to manage utilization and waste.

Climbing Health Care Costs Result in Elevated Employer Vigilance

Morgan Company report makes the case for expanding coverage for GLP-1s beyond diabetes treatment and into the weight loss class, but are employers on board?

Market Access and Pricing